MKMostafa Moghimi Kheirabady

Mostafa Moghimi Kheirabady

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mostafa Moghimi Kheirabady has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Obesity-related patterns of multimorbidity and their association with health-related quality of life in Iranian adults: a cross-sectional study

    by Mostafa Moghimi Kheirabady, Safdar Masoumi, Yosra Azizpour, Mohammad Amin Kharaghani, Mina Mirzad, Arash Bagherian Ghotbi, Nazila Rezaei, Ali Golestani

    Objective: To identify patterns of non-communicable disease (NCD) multimorbidity among Iranian adults and assess their associations with sociodemographic factors and health-related quality of life (HRQOL). Design: Cross-sectional analysis using data from the 2021 Iranian STEPS Survey, which follows the WHO STEPwise approach to collecting information on NCD risk factors. Setting: A community-based, nationally representative household survey conducted across Iran. Participants: A total of 17 517 Iranian adults with complete survey data were included. Of these, 56.7% were women and 67.4% lived in urban areas. Primary outcome measures: Latent class analysis was used to identify multimorbidity clusters based on chronic disease profiles, including myocardial infarction, stroke, asthma/chronic obstructive pulmonary disease, cancer, obesity (abdominal and defined by the body mass index), hypertension, diabetes, chronic kidney disease and dyslipidaemia. Associations between cluster membership, demographic characteristics and HRQOL (measured using the EuroQol Visual Analogue Scale, EQ-VAS) were examined using multinomial logistic regression. Results: Four distinct multimorbidity clusters were identified: obesity with severe metabolic syndrome (OSMS, 13.0%), obesity with early metabolic syndrome (OEMS, 39.3%), low comorbidity (LC, 42.4%) and non-obese cardiometabolic multimorbidity (NOCM, 5.2%). Cluster membership varied significantly by sex, age, education, occupation and insurance status. Older age, female sex, lower education, unpaid work and urban residence were associated with OSMS and OEMS, while male sex, older age, retirement and complementary insurance were associated with NOCM. EQ-VAS scores were significantly lower in the OSMS (β = −8.5; 95% CI −10.1 to −6.9), OEMS (β = −2.1; 95% CI −3.2 to −1.1) and NOCM (β = −6.2; 95% CI −8.2 to −4.2) clusters compared with the LC cluster. Conclusions: Multimorbidity clusters in Iran are heterogeneous and linked to demographic and socioeconomic factors. Obesity and social disadvantage strongly shape disease patterns and HRQOL. Findings highlight the need for integrated, equity-oriented policies addressing both clinical complexity and social determinants through prevention and coordinated care.

  • Open Access

    National and Subnational Burden of Cardiovascular Diseases in Iran from 1990 to 2021: Results from Global Burden of Diseases 2021 study

    by Mahsa Heidari-Foroozan, Melina Farshbafnadi, Ali Golestani, Sepehr Younesian, Hosein Jafary, Mohammad-Mahdi Rashidi, Ozra Tabatabaei-Malazy, Nazila Rezaei, Mostafa Moghimi Kheirabady, Arash Bagherian Ghotbi, et al.

    Introduction: In 2021, cardiovascular diseases (CVD) caused around 20.5 million deaths worldwide, making them a major health concern. Methods: Incidence, prevalence, death, years of life lost (YLL), years lived with disability (YLD), and disability-adjusted life years (DALYs) were the burden measures that were assessed. All measures are reported as both all-age numbers and age-standardized rates (ASR) with 95% uncertainty intervals (UI). Decomposition analysis was conducted on CVD incidence. Results: From 1990 to 2021, all-age CVD prevalence in Iran increased by 182.6% (2.9 to 8.3 million cases), with males consistently showing higher age-standardized prevalence rates (ASPR) than females (11,350 vs. 9,431 per 100,000 in 2021). ASPR remained stable nationally (9,956 to 10,386 per 100,000), peaking in adults ≥80 years. Incident cases rose by 159.6% (0.36 to 0.92 million), driven by population growth (49.5%) and aging (136.2%), while age-standardized incidence rates (ASIR) declined by 28.3% (1,337 to 1,197 per 100,000); with males (1,336) exhibiting higher rates than females (1,060) in 2021. All age deaths doubled (86,527 to 169,582) during this period, but age-standardized death rates (ASDR) decreased substantially by 42.97% (446 to 255 per 100,000). DALYs increased by 53.7% (2.4 to 3.7 million), though age-standardized DALY rates dropped 45.3% (9,096 to 4,977 per 100,000), dominated by ischemic heart disease (2,731 ASR) and stroke (1,229 ASR). High systolic blood pressure, dietary risks, and LDL cholesterol remained the leading contributors to DALYs nationwide. Conclusion: Iran’s rising CVD burden demands prioritizing cardiac care infrastructure in underserved provinces like Golestan, enforcing sodium reduction policies aligned with Iran’s existing trans-fat regulations, and integrating sex-specific programs such as tobacco control for males and community hypertension screening for women are critical. Multisectoral collaboration, including urban design promoting physical activity and subsidies for whole grains, must address provincial inequities exacerbated by Iran’s aging population and dietary risks.